Stem Cell Clinic

Karnataka:Community cord blood banking emerges as lifesaver – United News of India

By Stem Cell Doctors

More News 18 Nov 2020 | 11:29 PM

Hyderabad, Nov 18 (UNI) AICC Spokesperson Dr Sravan Dasoju slams the State Election Commission (SEC) for taking a U-turn on the distribution of flood relief funds to the victims.

Hyderabad, Nov 18 (UNI) A couple who allegedly cheated a bank of Rs 5.3 crore by submitting false documents to get loans, was arrested by the Cyberabad Police on Wednesday.

Hyderabad, Nov 18 (UNI) A 50-year-old woman waiting in queue at a Meeseva centre to apply for Rs 10,000 flood relief from the Telangana Government, collapsed and died at Tolichowki near here on Wednesday even as the stampede-like situation prevailed at Mee Seva centres in Hyderabad and surrounding areas where thousands of persons in queued up for applying to for flood relief.

Kochi, Nov 18 (UNI) Opposition Leader in Kerala Assembly Ramesh Chennithala on Wednesday alleged that the arrest of former PWD Minister VK Ebrahim Kunju was politically-motivated.

Bengaluru, Nov 18(UNI) Karnataka on Wednesday reported 1791 fresh cases of COVID-19 on Wednesday, taking the total number of infections in the state to 865931.

See the article here:
Karnataka:Community cord blood banking emerges as lifesaver - United News of India

Human sperm stem cells grown in lab, an early step toward infertility treatment – Jill Lopez

By Stem Cell Clinic

Infertility affects one in seven men of reproductive age worldwide. One idea for treating male sterility is spermatogonial stem cell (SSC) therapy. In this approach, sperm stem cells in the testis are transferred to a test tube, cultured and nudged into becoming fully fledged sperm. However, a key bottleneck has been identifying just the right conditions to get human SSCs to grow in the lab. There have been many attempts, but in most reported cases it was not clear whether the cells being cultured were actually SSCs, and no previously published method is routinely used.

Researchers at University of California San Diego School of Medicine have now developed a reliable method for culturing cells with the characteristics of human SSCs. Their work is published in the July 13, 2020 issue ofProceedings of the National Academy of Sciences.

"We think our approach -- which is backed up by several techniques, including single-cell RNA-sequencing analysis -- is a significant step toward bringing SSC therapy into the clinic," said senior author Miles Wilkinson, PhD, Distinguished Professor in the Department of Obstetrics, Gynecology and Reproductive Sciences at UC San Diego School of Medicine.

SSCs are what make it possible for men to father children beyond the age of 65. These specialized cells continually self-renew, making more SSCs, and develop into sperm so prolifically that men (and some transgender, non-binary and gender fluid people) produce more than 1,000 new sperm every few seconds.

Progress in the field has been hindered by the fact that it's extremely difficult to distinguish SSCs from other cells in the testes. It was a major step forward when several laboratories, including the Wilkinson team,recently useda technique called single-cell RNA sequencing to define the likely molecular characteristics specific to human SSCs.

In their latest effort, the Wilkinson team used its single-cell RNA sequencing information to purify what it thought might be human SSCs. Using a method called germ-cell transplantation, it showed that the cells it purified were indeed highly enriched in human SSCs. The team then gathered the profile of genes expressed in these human SSCs to make guesses as to the conditions that might best support their growth in the lab. Using more than 30 human testis biopsies, the researchers determined just the right conditions needed to culture immature germ cells with the characteristics of SSCs.

The key ingredient was an inhibitor of the AKT pathway, a cellular system that controls cell division and survival. The Wilkinson team determined that AKT inhibition maintains human SSCs by inhibiting development of later-stage sperm precursors. Several AKT inhibitors are currently used to treat cancer.

With that approach, the researchers were able to favor the culture of human cells with the molecular characteristics of SSCs for two-to-four weeks.

"Next, our main goal is to learn how to maintain and expand human SSCs longer so they might be clinically useful," Wilkinson said.

More:
Human sperm stem cells grown in lab, an early step toward infertility treatment - Jill Lopez

Global Stem Cell and Primary Cell Culture Medium Industry 2020 Market Research With Size, Growth, Manufacturers, Segments And 2026 Forecasts Research…

By Stem Cell Clinic

IndustryGrowthInsights has published a detailed report on the Stem Cell and Primary Cell Culture Medium market. This market research report was prepared after considering the COVID-19 impacts and monitoring the market for a minimum of five years. The report provides you with growing market opportunities, revenue drivers, challenges, pricing trends & factors, and future market assessments. Our research team has implemented a robust research methodology that includes SWOT analysis, Porters 5 Force analysis, and real-time analysis. Furthermore, they have conducted interviews with the industry experts to offer a report that helps the clients to formulate strategies accordingly.

The Global Stem Cell and Primary Cell Culture Medium Market has outlined the supply and demand scenario in the industry and provided a detailed analysis of the product developments, technology advancements, and competitive analysis in the market. It offers an in-depth analysis and all the information required by the new entrants and emerging players to stay ahead in the competition. This report includes information on the latest government policies, norms, and regulations that have and can affect the dynamics of the market.

The historical and forecast information provided in the report span between 2018 and 2026. The report provides detailed volume analysis and region-wise market size analysis of the market.

Get a sample copy of the report including the analysis of COVID-19 impact: https://industrygrowthinsights.com/request-sample/?reportId=170104

IGI has laid out a dedicated section for the prominent companies in the market which provides information on their revenue drivers, product innovation, and challenges they are facing during in the industry. This company profiling section includes industry players mergers, acquisitions, and collaborations which have helped them to leverage or impacted their market position. Besides this, the report is fragmented on the basis of the products, applications, and region-based analysis which imparts a holistic view and scope of the market.

The market research report also offers information on potential investment opportunities, strategic growth market analysis, and probable threats that will adhere to the client to systematically and creatively plan out the business models and strategies. The critical data analysis in the Stem Cell and Primary Cell Culture Medium market report is laid out in an upright way. This means that the information is represented in form of infographics, statistics, and uncomplicated graphs to make it an effortless and time-saving task for the client.

Complete Purchase of Latest Version Global Stem Cell and Primary Cell Culture Medium Market Study with COVID-19 Impact Analysis: https://industrygrowthinsights.com/checkout/?reportId=170104

Market Segmentation

The Stem Cell and Primary Cell Culture Medium market report is fragmented into product types, applications, and regional analysis. In this report, the product flow, distribution, and possible future innovations are bestowed in a detailed manner. It also provides accurate calculations for product sales in terms of volume and value.

The applications of the products are discussed in a coherent way which includes potential future applications.

The Stem Cell and Primary Cell Culture Medium market is classified into:

The Study is segmented by following Product Type:

Liquid Media Powder Media

Major applications/end-users industry are as follows:

Biopharmaceutical Manufacturing Tissue Engineering & Regenerative Medicine Gene Therapy Other

Geographical Analysis:

Major Companies in the Market:

Merck STEMCELL Technologies Irvinesci Cell Applications, Inc Biological Industries Miltenyi Biotec Swiss Medica Clinic Promocell Creative Biolabs Lifeline Cell Technology ScienCell Research Laboratories Osiris Therapeutics NuVasive Chiesi Pharmaceuticals JCR Pharmaceutical Pharmicell Medi-post Anterogen Molmed Takeda (TiGenix)

We also offers customization of the report. This means that the report can be tailored considering a particular product, application, and region, suiting the clients needs. Moreover, additional company profiles can be added if asked.

Request a discount on the report: https://industrygrowthinsights.com/ask-for-discount/?reportId=170104

The global Stem Cell and Primary Cell Culture Medium market report has gone through primary and secondary market research to provide a complete overview of the market. Our dedicated research analyst team has gathered information from the company and official government websites while interviewed directors and VPs of the company to prepare the market report effectively. This enables the client to get a thorough understanding of the market which is supported by the most accurate facts and figures.

The report provides entry-level and top-winning strategies which can assist the industry players to gain high ROI. Moreover, you can call our research analysts (24/7) to clear the clients doubts even after the report is bought by you. We also provides quarterly/yearly report updates to the clients inbox which helps them to stay relevant to the innovative trends in the market.

Get on the call with our research analyst if you have any particular doubts before buying the report @ https://industrygrowthinsights.com/enquiry-before-buying/?reportId=170104

About Us:

Our reports are more than just research reports to us. They are tools that enable us to maintain long-term relationships with our clients whom we honor and cherish. Our clients business growth is integral for not only them but also us. This is what differentiates us from other market research companies.

At IGI, we provide our expertise and guideline for success. Our team of efficient and experienced researchers and consultants provide progressive market intelligence reports that are accurate, authentic, and in-depth. This empowers the clients to make well-informed decisions.

Moreover, we offer market intelligence studies, ensuring relevant and fact-based research across a range of industries including chemicals and materials, energy, automobile, healthcare, consumer goods, and technology. Our deep understanding of many business environments across industries such as those mentioned above allows us to deliver tailor-made reports.

Contact Us:

Alex Mathews Head of Business Development Phone No.: +1 909 545 6473 Email [emailprotected] Website https://industrygrowthinsights.com Address 500 East E Street, Ontario, CA 91764, United States.

Read the original here:
Global Stem Cell and Primary Cell Culture Medium Industry 2020 Market Research With Size, Growth, Manufacturers, Segments And 2026 Forecasts Research...

Updated: FDA gives Cellectis all clear after patient death halted off-the-shelf CAR-T trial – Endpoints News

By Stem Cell Clinic

Four months after a patient death forced Cellectis to halt one of their off-the-shelf CAR-T trials, the FDA has given them the OK to start dosing patients again.

The Paris-based biotech said they changed the studys protocol to accommodate the agencys concerns, although they will still have to work with investigators to obtain local approval to restart the trial and start recruiting patients again. Prior its halt, the Phase I had sites in New York, New Jersey and Texas.

Cellectis did not disclose what the changes were, but after the initial hold, analysts suggested the company might monitor patient cytokine levels more closely, swap out of one of the chemotherapy drugs used or prevent patients who have previously received an experimental multiple myeloma CAR-T from enrolling.

The companys stock {CLLS} rose 5.6% on the news, from $19.70 to $20.80.

Though partnered with the new upstarts such as Arie Belldegruns Allogene, Cellectis, a 21-year-old company, has been working on off-the-shelf versions to the first CAR-Ts since before those CAR-Ts were approved.

One of three different solo projects now in the clinic, the halted study, MELANI-01, is testing a cell therapy for multiple myeloma. If effective, it could serve as a potentially easier way to manufacture and administer an alternative to the multiple myeloma CAR-Ts now nearing approval from J&J and Legend Biotech and from bluebird bio and Bristol Myers Squibb.

When they announced the hold, Cellectis CMO Carrie Brownstein said that the company had already independently decided to move forward with dose level 1 in the study. The patient who died had been the first to receive dose level 2, an infusion of 3 million cells per kilogram. They developed cytokine release syndrome, the hallmark side effect of CAR-T therapy, and died of cardiac arrest 25 days later.

The dose 1 level involves 1 million cells per kilogram.

The FDA has been on high alert for safety issues in cell therapy trials, and this wasnt the first time theyve paused a Cellectis study. Back in 2017, another patient death paused development of UCART123.

After some protocol adjustments, the therapy was allowed to go back into patients. It is now in a Phase I for acute myeloid leukemia.

More:
Updated: FDA gives Cellectis all clear after patient death halted off-the-shelf CAR-T trial - Endpoints News

Non-hereditary mutation acts as natural gene therapy for GATA2 deficiency – Health Europa

By Somatic Stem Cells

For the first time, researchers at the Center for Cell-Based Therapy (CTC) in Ribeiro Preto, Brazil, have identified a non-hereditary mutation in blood cells from a patient with GATA2 deficiency.

GATA2 deficiency is a rare autosomal disease caused by inherited mutations in the gene that encodes GATA-binding protein 2 (GATA2), which regulates the expression of genes that play a role in developmental processes and cell renewal.

An article on the study is publishedin the journalBlood.

The non-hereditary mutation may have acted as a natural gene therapy which prevented the disease from damaging the process of blood cell renewal. This meant that the patient did not develop such typical clinical manifestations as bone marrow failure, hearing loss, and lymphedema.

The researchers say that the findings pave the way for the use of gene therapy and changes to the process of checking family medical history and medical records for families with the hereditary disorder.

Luiz Fernando Bazzo Catto, first author of the article, said: When a germline [inherited] mutation in GATA2 is detected, the patients family has to be investigated because there may be silent cases.

The discovery was made when two sons were receiving medical treatment at the blood centre of the hospital run by FMRP-USP, both of which, in post-mortem DNA sequencing, showed germline mutations and GATA2 deficiency diagnosis. The researchers used next generation sequencing to estimate the proportion of normal blood cells in the fathers bone marrow, preventing clinical manifestations of GATA2 deficiency, and of cells similar to his childrens showing that 93% of his leukocytes had the mutation that protects from the clinical manifestations of GATA2 deficiency.

Following the sequencing of the fathers T-lymphocytes, the researchers found that the mutation occurred early in their lives and in the development of hematopoietic stem cells, which have the potential to form blood.

They also measured the activity of the blood cells, to see if they could maintain the activity of inducing normal cell production for a long time, by measuring the telomeres of his peripheral blood leukocytes. Telomeres are repetitive sequences of non-coding DNA at the tip of chromosomes that protect them from damage. Each time cells divide, their telomeres become shorter. They eventually become so short that division is no longer possible, and the cells die or become senescent.

The telomeres analysed by the researchers were long, indicating that the cells can remain active for a long time.

The researchers hypothesised that the existence of the somatic mutation in the fathers blood cells, and its restoration of the blood cell renewal process, may have contributed to the non-manifestation of extra-haematological symptoms of GATA2 deficiency such as deafness, lymphedema, and thrombosis.

Professor Rodrigo Calado, a corresponding author of the article, said: A sort of natural gene therapy occurred in this patient. Its as if he embodied an experiment and a medium-term prospect of analogous gene therapy treatment in patients with GATA2 deficiency.

The findings help us understand better how stem cells can recover by repairing an initial genetic defect.

Recommended Related Articles

Here is the original post:
Non-hereditary mutation acts as natural gene therapy for GATA2 deficiency - Health Europa

Cell Therapy Market Attractiveness, Competitive Landscape and Key Players MEDIPOST, Kolon TissueGene, NuVasive, Fibrocell Science – The Think…

By Somatic Stem Cells

The Insight Partners adds Cell Therapy Market Forecast to 2027 COVID-19 Impact and Global Analysis to its store providing analysis of the current and future market competition in the market. Insightful review of the key industry drivers, opportunities, barriers and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

The study provides details such as the market share, Market Insights, Strategic Insights, Segmentation and key players in the Cell Therapy Market.

Download PDF Report Sample with statistical info @ https://www.theinsightpartners.com/sample/TIPRE00009666/

(*If you have any special requirements, please let us know and we will offer you the report as you want.)

Cell therapy (CT) is the process of transplanting human cells to replace or repair damaged tissue or cells. Various methods can be used to carry out cell therapy. For instance, hematopoietic stem cell transplantation, also known as bone marrow transplant, is the most widely used cell therapy. It is used to treat a variety of blood cancers and blood-related conditions.

Some of the Major Market Players Are:

Kolon TissueGene, Inc. MEDIPOST JCR Pharmaceuticals Co. Ltd. Stemedica Cell Technologies, Inc. Osiris Therapeutics, Inc. NuVasive, Inc. Fibrocell Science, Inc. Vericel Corporation Cells for Cells Celgene Corporation

Note The Covid-19 (coronavirus) pandemic is impacting society and the overall economy across the world. The impact of this pandemic is growing day by day as well as affecting the supply chain. The COVID-19 crisis is creating uncertainty in the stock market, massive slowing of supply chain, falling business confidence, and increasing panic among the customer segments. The overall effect of the pandemic is impacting the production process of several industries. This report on Cell Therapy Market provides the analysis on impact on Covid-19 on various business segments and country markets. The reports also showcase market trends and forecast to 2027, factoring the impact of Covid -19 Situation.

The global cell therapy market is segmented on the basis of therapy type, product, technology, application, end user. Based on the therapy type the market is classified as autologous, and allogeneic. Based on product the market is segmented as equipment, consumables, software and services. Based on technology the market is segmented as somatic cell technology, cell immortalization technology, viral vector technology, genome editing technology, cell plasticity technology, and three-dimensional technology. Based on application the market is classified as oncology, cardiology, orthopedic, wound management and others. And based on end user the market is divided into hospitals, regenerative medicine centers, and research institutes.

The objective of the researchers is to find out the sales, value, and status of the In Cell Therapy industry at the international levels. While the status covers the years of 2020 2027, the forecast is for the period 2020 2027 that will enable market players to not only plan but also execute strategies based on the market needs.

The study wanted to focus on key manufacturers, competitive landscape, and SWOT analysis for the In Cell Therapy Market. Apart from looking into the geographical regions, the report concentrated on key trends and segments that are either driving or preventing the growth of the industry. Researchers have also focused on individual growth trends besides their contribution to the overall market.

An outline of the regional analysis:

Purchase This Report at: https://www.theinsightpartners.com/buy/TIPRE00009666/

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Life Science, Technology, Healthcare, Manufacturing, Automotive and Defense, Food Beverages, Chemical etc.

Contact Us:

Call: +1-646-491-9876

Email: [emailprotected]

View post:
Cell Therapy Market Attractiveness, Competitive Landscape and Key Players MEDIPOST, Kolon TissueGene, NuVasive, Fibrocell Science - The Think...

How CAR-T Cell Therapy is Being Used in the Field of Blood Cancer Treatment – Curetoday.com

By Stem Cell Doctors

Currently only approved for the treatment of B-cell malignancies, CAR-T cell therapy is a relatively new treatment option that researchers are learning more about each day, according to Amelia Langston, MD.

Langston, a professor and Executive Vice Chair of the Department of hematology and medical oncology at the Winship Cancer Institute of Emory University, recently presented a session on CAR-T cell therapy at CURE's Educated Patient Leukemia & Lymphoma Summit, touching on not just how the treatment has evolved, but where it could be going in the near future.

Langston began by defining one of the major problems that researchers are trying to solve by utilizing CAR-T cell therapy: making immunotherapy a reality for more patients with blood cancer. There are a few methods that are currently in use, including allogeneic stem cell transplantation, monoclonal antibody therapy, and checkpoint inhibitors drugs that call upon a number of natural cellular immune responses.

At its core, the main concept of novel therapeutics is to bring the immune cells and the tumor cells together in a way that activates the immune cells to kill those cells that carry a specific target or targets. The goal is to also eliminate some of the complexities of the T-cell immune response and, according to Langston, potentially recruit other immune players into the mix.

The process of CAR-T cell therapy begins with T cells that are collected from a patient, Langston explained, and then manipulated in a laboratory. We then introduce a genetically engineered chimeric antigen receptor (CAR) construct that confers specificity for an antigen on the surface of the tumor cell. And that results in killing of the tumor.

It is worth noting, Langston said, that the manufacturing of these CAR-T cells is not trivial. Once the T cells are extracted, modified, and reproduced in large quantities, the patient then needs to be prepared with what doctors call lymphodepleting chemotherapy. This essentially makes room in the in the patient's immune system for the new T cells to get into the body and expand. After thats done, the T cells are delivered to the patient, where they expand inside the patient and get to work.

The first target that has been successfully applied to CAR-T cell therapy is a molecule called CD19, Langston went on to explain. This is a very attractive target because it corresponds to many of the different B-cell malignancies, with three different options currently approved by the FDA:

While it is an attractive option given its efficacy, CAR-T cell therapy comes with significant and unique toxicities, according to Langston namely, cytokine release syndrome.

The cells divide very rapidly in the patient, and they create a sort of a cytokine storm as a consequence of that rapid division, she said. This so-called cytokine release syndrome is characterized by high fevers, hypotension, diffuse capillary leak and swelling, and is associated with a lot of inflammatory markers. And if this complication is not identified quickly and managed appropriately, this is an absolutely life-threatening complication. The bright spot in this potential side effect is that effective interventions to help manage it do exist, mainly in the form of Actemra (tocilizumab).

Neurologic toxicities can also arise as a result of CAR-T cell therapy, and can also be life-threatening. Patients could have anything from a little bit of trouble with their memory, all the way to seizures and brain swelling and even death, Langston said. However, she did note, this is a reversible complication if it is identified and treated very quickly.

A third issue that can occur is B-cell aplasia, where the manufactured CAR T-cells attack normal B-cells that also express CD19, putting patients at higher risk of developing infections. Like the other toxicities related to CAR-T cell therapy, this condition can be treated as well, with intravenous immunoglobulin replacement therapy.

Citing CAR-T cell therapy success stories like that of Emily Whitehead, Langston concluded with a look at not just how this treatment can be refined and made more effective for patients, but what impact it could have on malignancies outside of the blood cancer space.

I think one of the most important areas (we are looking at) is how do we make the CAR-T cell concept work better? Langston asked. Can we add other immune modulators and stimulants into the mix to try to enhance persistence of those CAR-T cells? What about the fact that we have patients with T-cells that are really pretty beaten up from their prior therapies? Can we rejuvenate their T-cells before they are transduced? Or after transduction for that matter, in order to make the CAR-T cells more robust and more powerful? Can we develop new CAR constructs that will enhance the activity without maximizing toxicity?

When it comes to solid tumors, Langston concluded, her own institution is one of many that is currently investigating the possibilities. We have an ongoing study (at Emory) in lung cancer, we have another study in head neck cancer, and were beginning to get into breast cancer as well, she said.

While its challenging to identify targets in these cancers, Langston said, there is hope. It becomes more challenging when we look at some of the solid cancers, but there's a lot of promising data in early phase studies to suggest that this will be possible in the future.

For more news on cancer updates, research and education, dont forget tosubscribe to CUREs newsletters here.

Original post:
How CAR-T Cell Therapy is Being Used in the Field of Blood Cancer Treatment - Curetoday.com

Cell Separation Beads Market to Witness Robust Expansion Throughout the Forecast Period 2018-2028 – The Daily Philadelphian

By Stem Cell Doctors

With 1000+ market research reports and 1 billion+ data points, Future Market Insights (FMI) serves each and every requirement of the clients operating in the global healthcare, pharmaceuticals, and medical device industries. FMI deploys digital intelligence solutions to offercompelling insights to report buyersthat help them in overcoming market challenges, especially at the time of a crisis. Our dedicated team of professionals performs an extensive survey for gathering accurate information associated with the market.

FMI, in its upcoming business report, elaborates the historical and current scenario of the global Cell Separation Beads market in terms of production, consumption, volume, and value. The report scrutinizes the market into various segments, regions and players on the basis of demand pattern and growth prospects.

Crucial information and forecast statistics covered in the Cell Separation Beads market report will arm both existing and emerging market players with necessary insights to craft long-term strategies as well as maintain business continuity during a crisis such as the ongoing COVID-19 pandemic.

COVID-19 Impact Analysis on Cell Separation Beads Market

The recent outbreak of the COVID-19 has turned the spotlight on the healthcare industry, and subsequently impacted the Cell Separation Beads market. Severe shortages of critical medical supplies and a rapid rise in number of COVID-19 cases have resulted into a revolution rather than evolution in the healthcare ecosystems. Consequently, the impact is noticeable in the Cell Separation Beads market.

Following governments measures, particularly social distancing norms and stay-at-home orders, doctors are delaying or postponing elective surgeries unless critical to prevent the spread of the virus to individuals with comorbidities or chronic conditions. Additionally, movement restrictions and supply chain disruptions have created a logistical nightmare for market players, leading to severe product shortages in the global marketplace.

The FMIs report includes an interesting chapter on preliminary impact of the COVID-19 on the Cell Separation Beads market. This allows both leading and emerging market players to understand the market scenario during a crisis and aids them in making sound decisions to gain a distinct competitive edge.

To Get the Sample Copy of Report visit @

https://www.futuremarketinsights.com/reports/sample/rep-gb-7348

Why Choose Future Market Insights

Discounted prices for new customers! Offer expires soon!

Cell Separation Beads Market: Segmentation

Valuable information covered in the FMIs Cell Separation Beads market report has been segregated into key segments and sub-segments.

By Cell type

By Application

Cell Separation Beads Market: Competition Analysis

The FMIs study presents a comprehensive analysis of global, regional, and country-level players active in the Cell Separation Beads market.Competitive information detailed in the Cell Separation Beads market report has been based on innovative product launches, distribution channels, local networks, industrial penetration, production methods, and revenue generation of each market player. Furthermore, growth strategies and mergers & acquisitions (M&A) activities associated with the players are enclosed in the Cell Separation Beads market report.

Key players covered in the report include:

Request to View [emailprotected]

https://www.futuremarketinsights.com/toc/rep-gb-7348

Important Questions Answered in the Cell Separation Beads Market Report

Key Offerings of the Report

Read the original post:
Cell Separation Beads Market to Witness Robust Expansion Throughout the Forecast Period 2018-2028 - The Daily Philadelphian

Election results for California Propositions 14, 18, 23, and 24 – FOX 11 Los Angeles

By Stem Cell Doctors

LOS ANGELES - Twelve statewide propositions appeared on the California ballot for the November 3 election and voters will decide what becomes law.Those measures cover an array of topics including stem cell research, primary voting for 17-year-olds, kidney dialysis clinics and data privacy rules.

RELATED:Election Results: California Propositions

California voters pass Proposition 14

Proposition 14 would allow California to sell $5.5 billion in general obligationbonds for continued stem cell and medical research. The measure builds on Prop 71 that was enacted by voters in 2004 to support stem cell research and authorized $3 billion in bonds. According to theLeague of Women Voters of California,almost all the funds from the sale of the bonds authorized by Prop 71 have been spent.

California voters rejectProposition 18

Proposition 18 would allow 17-year-olds to vote in primaries and special elections, provided they turn 18 by the November general election. At least 18 states and Washington, D.C., have adopted laws that let people younger than 18 vote in certain circumstances.

Advocates say any chance to get people in the habit of voting should be encouraged. Besides, they say, young people whose birthdays fall between the primary and the general election are at an unfair disadvantage.

The Election Integrity Project California, the main opponent to Proposition 18, says that 17-year-olds are still considered children under the law and have no business deciding elections.

California voters reject Proposition 23

Proposition 23 was placed on the ballot by unions that represent health care workers and has attracted more than $110 million in political spending to persuade voters.

Opponents, financed by dialysis clinic companies, say that under that mandate, between two and three doctors would be required at every facility because most are open at least 16 hours a day, creating a financial burden that could lead some clinics to close.

Proposition 23 is the second attempt by the unions to increase regulation of dialysis clinics in California, where DaVita Inc. and Fresenius Medical Care two of the countrys largest for-profit dialysis providers operate about three-quarters of the states dialysis market.

California voters pass Proposition 24

Proposition 24 would update a 2018 law that gave Californians the right to know what information companies collect about them online, the right to get that data deleted and the right to opt out of the sale of their personal information.

The new measure would triple the fines for companies that violate kids privacy or break laws on the collection and sale of childrens private information. It would create a dedicated state agency to enforce the new law, with an annual budget of $10 million.

It also aims to close some loopholes that proponents say companies like Facebook, Google and Spotify have exploited.

Get your top stories delivered daily! Sign up forFOX 11s Fast 5 newsletter. And, get breaking news alerts in the FOX 11 News app. Download foriOS or Android.

Original post:
Election results for California Propositions 14, 18, 23, and 24 - FOX 11 Los Angeles

FUJIFILM Cellular Dynamics and Lonza Agree to Expand the Availability and Use of Induced Pluripotent Stem Cell Technology – BioSpace

By Stem Cell Clinic

About Lonza

At Lonza, we combine technological innovation with world class manufacturing and process excellence. Together, these enable our customers to deliver their discoveries in the healthcare, preservation, and protection sectors.

We are a preferred global partner to the pharmaceutical, biotech and specialty ingredients markets. We work to prevent illness and promote a healthier world by enabling our customers to deliver innovative medicines that help treat or even cure a wide range of diseases. We also offer a broad range of microbial control solutions, which help to create and maintain a healthy environment.

Founded in 1897 in the Swiss Alps, Lonza today operates in 120 sites and offices in more than 35 countries. With approximately 15,500 full-time employees, we are built from high-performing teams and of individual employees who make a meaningful difference to our own business, as well as the communities in which we operate. The company generated sales of CHF 5.9 billion in 2019 with a CORE EBITDA of CHF 1.6 billion. Find out more atwww.lonza.comand follow us on Twitter @LonzaGroup or Facebook @LonzaGroupAG.

About FUJIFILM

FUJIFILM Cellular Dynamics, Inc. (FCDI) is a leading developer and manufacturer of human induced pluripotent stem cells (iPSCs) utilized in drug discovery and cell therapies. FCDI is using its expertise in iPSC technologies to develop a robust cell therapeutics pipeline to address unmet medical needs in areas such as age-related macular degeneration, retinitis pigmentosa and immuno-oncology. For its partners, FCDI utilizes its iPSC platform to advance the progress of therapeutic candidates in the clinic and provides contract development and manufacturing (CDMO) services. In addition to cell therapy, FCDI also offers life science research tools including the companys inventoried iCell products, which are available in almost any cell type and are sourced from multiple cell lines which can be applied for target identification as well as toxicity testing. The company also offers custom cell development services and cell banking. FCDIs goal is to leverage the vast utility of iPSCs to advance human health and improve the quality of life for patients around the world. For more information, please visit:https://fujifilmcdi.com

FUJIFILM Holdings Corporation, Tokyo, Japan, brings cutting edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. Its proprietary core technologies contribute to the various fields including healthcare, highly functional materials, document and imaging products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the year ended March 31, 2020, the company had global revenues of $21 billion, at an exchange rate of 109 yen to the dollar. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For more information, please visit:www.fujifilmholdings.com

Lonza Contact Details

FUJIFILM Contact Details:

Christine Jackman

FUJIFILM

(914) 789-8523

christine.jackman@fujfilm.com

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (SGX-ST). Lonza Group Ltd is not subject to the SGX-STs continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this newsrelease. All product and company names herein may be trademarks of their registered owners.

See the article here:
FUJIFILM Cellular Dynamics and Lonza Agree to Expand the Availability and Use of Induced Pluripotent Stem Cell Technology - BioSpace

→←